background: interferon beta-la and -1b have been increasingly used for the treatment of multiple sclerosis (ms). the most frequent systemic adverse effects are flu-like symptoms. laboratory abnormalities include asymptomatic leukopenia and elevated hepatic transaminases. myelodysplastic syndrome (mds) refers to a spectrum of hematological disorders which can occur in different situations. sever...

BACKGROUND Women with multiple sclerosis (MS) are advised to discontinue interferon-beta therapy before trying to conceive. Unplanned pregnancies occur and risks related to exposure remain unclear. METHODS To determine pregnancy outcomes following interferon-beta therapy, we examined pregnancies from a global drug safety database containing individual case safety reports received in the post-...

OBJECTIVE To examine the hypothesis that increases in depression after initiation of treatment with interferon beta-1a for multiple sclerosis can be explained as representing a return to pretreatment levels of depression. DESIGN Level of depression in patients with multiple sclerosis was assessed at 3 time points: 2 weeks before initiation of interferon beta-la treatment, at initiation of tre...

This is a descriptive case report of a 30-year-old man with massive epistaxis, echymosis on arms, abnormal CBC and increased plasma urea and creatinine level (i.e. above normal range). Probably, these are as side effects of interferon beta-1a injection. This is the first report according to our literature search (Pub Med, Google scholar, ISI web of knowledge, ProQuest, MD consult, Science Direc...

IL-4: Interleukin 4 IFN-b: Interferon beta IFN-b1a: Interferon beta-1a MS: Multiple sclerosis SSc: Systemic sclerosis Th2: T helper 2 INTRODUCTION Interferon beta-1a (IFN-b1a) is a cytokine therapy used in the treatment of relapsing-remitting multiple sclerosis. The most common adverse injection site reactions include local erythema, pain, and induration. Other less frequently encountered react...

AIM Subcutaneous (s.c.) peginterferon beta-1a injected once every 2 weeks and s.c. interferon beta-1a injected three times per week (Rebif®) have demonstrated efficacy in relapsing-remitting multiple sclerosis, but direct comparisons of pharmacological activity and tolerability between the two products are lacking. COMPARE was an open label, crossover, pharmacokinetic (PK) study evaluating drug...

Background and Aims: Chronic hepatitis C is one of the most important etiologies of cirrhosis and hepatocellular carcinoma worldwide. Clinical condition of hepatic patients and the outcome of chemotherapy are under impact of Hepatitis C virus (HCV) genotypes. Therefore, HCV genotyping is important for prediction of success of chemotherapy and progression of liver diseases. Methods: In thi...